These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 17545771)

  • 1. Defensins and other antimicrobial peptides in inflammatory bowel disease.
    Wehkamp J; Schmid M; Stange EF
    Curr Opin Gastroenterol; 2007 Jul; 23(4):370-8. PubMed ID: 17545771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defensin-immunology in inflammatory bowel disease.
    Wehkamp J; Stange EF; Fellermann K
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
    Wehkamp J; Schmid M; Fellermann K; Stange EF
    J Leukoc Biol; 2005 Apr; 77(4):460-5. PubMed ID: 15618294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
    Wehkamp J; Stange EF
    Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease.
    Schmid M; Fellermann K; Fritz P; Wiedow O; Stange EF; Wehkamp J
    J Leukoc Biol; 2007 Apr; 81(4):907-15. PubMed ID: 17200145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
    Ramasundara M; Leach ST; Lemberg DA; Day AS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.
    Kübler I; Koslowski MJ; Gersemann M; Fellermann K; Beisner J; Becker S; Rothfuss K; Herrlinger KR; Stange EF; Wehkamp J
    Aliment Pharmacol Ther; 2009 Sep; 30(6):621-33. PubMed ID: 19549264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paneth cell defensins: key effector molecules of innate immunity.
    Bevins CL
    Biochem Soc Trans; 2006 Apr; 34(Pt 2):263-6. PubMed ID: 16545089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NODs in defence: from vulnerable antimicrobial peptides to chronic inflammation.
    Peyrin-Biroulet L; Vignal C; Dessein R; Simonet M; Desreumaux P; Chamaillard M
    Trends Microbiol; 2006 Oct; 14(10):432-8. PubMed ID: 16942880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease.
    Wang G; Stange EF; Wehkamp J
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1049-57. PubMed ID: 18039087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paneth cells and the innate immune response.
    Wehkamp J; Stange EF
    Curr Opin Gastroenterol; 2006 Nov; 22(6):644-50. PubMed ID: 17053443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms.
    Dignass AU; Baumgart DC; Sturm A
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():9-17. PubMed ID: 15352888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues.
    Wehkamp J; Chu H; Shen B; Feathers RW; Kays RJ; Lee SK; Bevins CL
    FEBS Lett; 2006 Oct; 580(22):5344-50. PubMed ID: 16989824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced mucosal antimicrobial activity in Crohn's disease of the colon.
    Nuding S; Fellermann K; Wehkamp J; Stange EF
    Gut; 2007 Sep; 56(9):1240-7. PubMed ID: 17456510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
    Peyrin-Biroulet L; Chamaillard M
    J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defensins and Paneth cells in inflammatory bowel disease.
    Shi J
    Inflamm Bowel Dis; 2007 Oct; 13(10):1284-92. PubMed ID: 17567878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Events at the host-microbial interface of the gastrointestinal tract. V. Paneth cell alpha-defensins in intestinal host defense.
    Bevins CL
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G173-6. PubMed ID: 16014978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential expression of vasoactive intestinal peptide receptor 1 expression in inflammatory bowel disease.
    Yukawa T; Oshitani N; Yamagami H; Watanabe K; Higuchi K; Arakawa T
    Int J Mol Med; 2007 Aug; 20(2):161-7. PubMed ID: 17611633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications.
    Mankertz J; Schulzke JD
    Curr Opin Gastroenterol; 2007 Jul; 23(4):379-83. PubMed ID: 17545772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immune dysfunction in inflammatory bowel disease.
    Gersemann M; Wehkamp J; Stange EF
    J Intern Med; 2012 May; 271(5):421-8. PubMed ID: 22324936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.